109 related articles for article (PubMed ID: 3305224)
41. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.
Kahn SB; Begg CB; Mazza JJ; Bennett JM; Bonner H; Glick JH
J Clin Oncol; 1984 Aug; 2(8):865-70. PubMed ID: 6379120
[TBL] [Abstract][Full Text] [Related]
42. [Advances in the treatment of acute myeloid leukemia in children. Experience of the Argentinian Group of Acute Leukemia Treatment and the Latin American Group of Malignant Hemopathies Treatment 1967-1987].
Freigeiro D; Scaglione C; Santarelli MT; Sackmann Muriel F; Jiménez E; Pavlovsky S; Bustelo P; Richard L; Kohan R; Kvicala R
Sangre (Barc); 1989 Jun; 34(3):221-8. PubMed ID: 2669186
[TBL] [Abstract][Full Text] [Related]
43. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
45. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
[TBL] [Abstract][Full Text] [Related]
46. Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
Büchner T; Hiddemann W; Blasius S; Koch P; Maschmeyer G; Tirier C; Sodomann H; Kuse R; Thiel E; Ludwig WD
Haematol Blood Transfus; 1990; 33():261-6. PubMed ID: 2182419
[No Abstract] [Full Text] [Related]
47. Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia.
Palva IP; Almqvist A; Elonen E; Hänninen A; Jouppila J; Järventie G; Koivunen E; Kätkä K; Lahtinen R; Oivanen T
Eur J Haematol; 1991 Sep; 47(3):229-33. PubMed ID: 1915807
[TBL] [Abstract][Full Text] [Related]
48. Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
Jehn U; Knüppel W; Wilmanns W
Onkologie; 1988 Feb; 11(1):13-7. PubMed ID: 3283620
[TBL] [Abstract][Full Text] [Related]
49. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.
Woods WG; Ruymann FB; Lampkin BC; Buckley JD; Bernstein ID; Srivastava AK; Smithson WA; Benjamin DR; Feig SA; Kim TH
Cancer; 1990 Sep; 66(6):1106-13. PubMed ID: 2205352
[TBL] [Abstract][Full Text] [Related]
50. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.
de Nully Brown P; Hoffmann T; Hansen OP; Boesen AM; Grønbaek K; Hippe E; Jensen MK; Thorling K; Storm HH; Pedersen-Bjergaard J
Leukemia; 1997 Jan; 11(1):37-41. PubMed ID: 9001416
[TBL] [Abstract][Full Text] [Related]
51. Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.
Bigelow CL; Kopecky K; Files JC; Head D; Lipschitz DA; Grever M; Appelbaum FR
Am J Hematol; 1995 Apr; 48(4):228-32. PubMed ID: 7717369
[TBL] [Abstract][Full Text] [Related]
52. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Vogler WR; Velez-Garcia E; Omura G; Raney M
Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
[No Abstract] [Full Text] [Related]
53. The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis.
Creutzig U; Ritter J; Riehm H; Budde M; Schellong G
Haematol Blood Transfus; 1987; 30():71-5. PubMed ID: 3305225
[No Abstract] [Full Text] [Related]
54. Post-remission therapy in acute myeloblastic leukemia. A randomized trial comparing early consolidation plus maintenance versus maintenance therapy alone.
Maldonado J; Gardella S; Rodriguez Fernandez JM; Parody R; Muncunill J; Vivancos P; Alonso C; Hernandez-Nieto L; Domingo A; Marin J
Acta Oncol; 1989; 28(2):223-6. PubMed ID: 2660862
[TBL] [Abstract][Full Text] [Related]
55. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
56. Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
Presant CA; Berger NA; Klahr C; Phillips GL
Cancer; 1980 Jul; 46(1):22-8. PubMed ID: 6930320
[TBL] [Abstract][Full Text] [Related]
57. Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia.
Nowrousian MR; Pfeiffer R; Schaefer UW; Osieka R; Niederle N; Anders C; Schmidt CG
Haematol Blood Transfus; 1987; 30():352-5. PubMed ID: 3305206
[No Abstract] [Full Text] [Related]
58. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
59. Short term therapy (STT) for acute myelogenous leukaemia (AML).
Rohatiner AZ; Battista R; Bassan R; Love S; Oza AM; Whelan JS; Lim J; Buelli M; Viero P; D'Emillio A
Leukemia; 1992; 6 Suppl 2():85-8. PubMed ID: 1578952
[TBL] [Abstract][Full Text] [Related]
60. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
Champlin R; Gajewski J; Nimer S; Vollset S; Landaw E; Winston D; Schiller G; Ho W
J Clin Oncol; 1990 Jul; 8(7):1199-206. PubMed ID: 1694236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
